Abbott's Knoll Advantage
The recent launch of Humira is the clearest sign of how valuable the Knoll acquisition has proved for Abbott. Yet the deal's rewards have come not only from the assets Knoll had to offer, but from what Abbott chose to do with them.
You may also be interested in...
COVID-19 has triggered a dramatic shift toward virtual consultations and telemedicine, encouraged by more relaxed regulations and payer support.
As the global shut-down caused by the coronavirus pandemic continues, sponsors are rushing to adapt clinical trials that can move to partial or completely remote monitoring, allowing patients to remain in their homes but continue to participate in studies. And the outbreak may have another silver lining for the biopharma industry, a chance to rebuild its reputation.
Oncology and rare diseases dominate the industry pipeline, fuelled by science, regulatory tailwinds and high prices. But as the world grapples with coronavirus, and with heart disease still the top killer, can our systems fund treatments for more prevalent conditions?